A new study published in Scientific Reports indicates that amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) have an extremely high geographic association, even after controlling for ...
Multiple sclerosis (MS) is an autoimmune condition in which the protective insulation surrounding neurons in the brain and spinal cord is erroneously attacked. This can cause a wide variety of serious ...
Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These drugs help regenerate the protective myelin sheath and balance immune ...
Eyeing a drug that it believes holds peak annual sales potential of $12 billion in the U.S. alone, Zenas BioPharma has struck a licensing deal with China-based InnoCare Pharma that could be worth more ...
Women with relapsing-remitting multiple sclerosis (MS), particularly after menopause, experienced a higher risk of relapse-independent worsening, whereas men showed a greater worsening of disability ...
HENRICO COUNTY, Va. — Walking into Mimi Murdock's Henrico home is a lot like stepping into a painting. "My house, everything's fluid, you know, it's just going to change," Murdock said. "I'm a visual ...
She was diagnosed with multiple sclerosis in 2018. Selma Blair, 53, is giving fans an update on her battle with the autoimmune disease. Speaking on “Today” on NBC, the “Cruel Intentions” actress from ...
Actor, author and advocate Selma Blair joins TODAY to talk about taking on new projects as she remains “relapse-free” for a couple years from multiple sclerosis. Blair opens up about embarking on new ...
EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Sanofi SNY announced that the FDA has extended the target action date for its new drug application (NDA) for tolebrutinib by three months. The NDA is seeking approval of tolebrutinib, an oral and ...
On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback